Evidence map›Paper›PMID 36507650›Full record

ReviewDiabetes care2023

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

Nuha A ElSayed, Grazia Aleppo, Vanita R Aroda, Raveendhara R Bannuru, Florence M Brown, Dennis Bruemmer, Billy S Collins, Marisa E Hilliard, Diana Isaacs, Eric L Johnson and 11 more

4 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06080802. Cited by 460 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
460citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06080802 phase2 / phase3unknown status

The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction

Ran2023Enrolled80Registered outcomes8Posted comparisons0ConditionsDiabete Type 2, Heart Failure With Preserved Ejection FractionArmsMetformin
PMID 37137593other papers from this trial
Open the trial in the graph
NCT06759922 phase4completedstarted 2025, after this paper: background citation

Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy

Ran2025Enrolled172Registered outcomes2Posted comparisons0ConditionsType 2 Diabetes MellitusArmsTab Metformin + Tab Empagliflozin, Tab Metformin + Tab Empagliflozin + Tab Sitagliptin, Tab Metformin + Tab Glimepiride, Tab Metformin +Tab Sitagliptin
PMID 34388848PMID 35309368PMID 32690918PMID 32041141PMID 31081587PMID 30961501PMID 33736819PMID 38223523PMID 37809225PMID 36151309PMID 34385345PMID 35668219other papers from this trial
Open the trial in the graph
NCT06410768 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Evaluating the Feasibility of a Future Trial-based Economic Evaluation of a Multistage Shared Decision-making Program for the Treatment of Type 2 Diabetes Mellitus: a Pilot Study

TypeinterventionalSponsorMaastricht University Medical CenterRan2024 to 2025Enrolled40ConditionsDiabetes Mellitus, Type 2Armsmultistage shared decision-making program
NCT06999356 narecruitingnot on this mapstarted 2025, after this paper: background citation

Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitoring In Predominantly Hispanic/Latino Adults With Non-Insulin Treated Type 2 Diabetes And An HbA1c > 9%

TypeinterventionalSponsorSutter HealthRan2025 to 2026Enrolled200ConditionsDiabetes, NutritionArmsCGM Device
3 · Its place in the literature

Who cites it

460 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Efficacy and safety ofFrontiers in pharmacology · 2025
    Trial
  20. Trial

400 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nuha A ElSayed
Grazia Aleppo
Vanita R Aroda
Raveendhara R Bannuru
Florence M Brown
Dennis Bruemmer
Billy S Collins
Marisa E Hilliard
Diana Isaacs
Eric L Johnson
Scott Kahan
Kamlesh Khunti
Jose Leon
Sarah K Lyons
Mary Lou Perry
Priya Prahalad
Richard E Pratley
Jane Jeffrie Seley
Robert C Stanton
Robert A Gabbay
on behalf of the American Diabetes Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Indexed as

Diabetes MellitusEndocrinologyHumansReference StandardsSocieties, MedicalStandard of Care

Identifiers

PMID36507650
PMCPMC9810476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.